208 related articles for article (PubMed ID: 3283299)
1. Soluble glucan and lymphokine-activated killer (LAK) cells in the therapy of experimental hepatic metastases.
Sherwood ER; Williams DL; McNamee RB; Jones EL; Browder IW; Di Luzio NR
J Biol Response Mod; 1988 Apr; 7(2):185-98. PubMed ID: 3283299
[TBL] [Abstract][Full Text] [Related]
2. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.
Lafreniere R; Rosenberg SA
Cancer Res; 1985 Aug; 45(8):3735-41. PubMed ID: 3893689
[TBL] [Abstract][Full Text] [Related]
3. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
4. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
Lafreniere R; Rosenberg SA
J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
[TBL] [Abstract][Full Text] [Related]
5. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
6. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
[TBL] [Abstract][Full Text] [Related]
7. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
8. Enhanced antimetastatic activity of lymphokine-activated killer cells purified and expanded by their adherence to plastic.
Schwarz RE; Vujanovic NL; Hiserodt JC
Cancer Res; 1989 Mar; 49(6):1441-6. PubMed ID: 2784350
[TBL] [Abstract][Full Text] [Related]
9. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy of murine hepatic metastases with lymphokine-activated killer cells expanded in serum-free media and recombinant interleukin 2.
Lafreniere R; Borkenhagen K; Bryant LD; Huchcroft S
Cancer Res; 1989 May; 49(9):2409-14. PubMed ID: 2565160
[TBL] [Abstract][Full Text] [Related]
11. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.
Mulé JJ; Shu S; Rosenberg SA
J Immunol; 1985 Jul; 135(1):646-52. PubMed ID: 3889158
[TBL] [Abstract][Full Text] [Related]
12. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
13. Use of lymphokine-activated killer cells to prevent bone marrow graft rejection and lethal graft-vs-host disease.
Azuma E; Yamamoto H; Kaplan J
J Immunol; 1989 Sep; 143(5):1524-9. PubMed ID: 2668409
[TBL] [Abstract][Full Text] [Related]
14. Effects of cancer immunotherapy with indomethacin and interleukin-2 on murine hemopoietic stem cells.
Saarloos MN; Khoo NK; Lala PK
Cancer Res; 1992 Dec; 52(23):6452-62. PubMed ID: 1423293
[TBL] [Abstract][Full Text] [Related]
15. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy of cancer with lymphokine-activated killer cells and recombinant interleukin-2.
Rosenberg SA; Mulé JJ
Surgery; 1985 Sep; 98(3):437-44. PubMed ID: 3898451
[TBL] [Abstract][Full Text] [Related]
17. Ineffectiveness of adoptive chemoimmunotherapy with lymphokine-activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murine bladder cancer.
Lee K; O'Donnell RW; Cockett AT
J Biol Response Mod; 1988 Feb; 7(1):43-53. PubMed ID: 3259620
[TBL] [Abstract][Full Text] [Related]
18. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
Wakizaka Y
Hokkaido Igaku Zasshi; 1992 Jul; 67(4):475-87. PubMed ID: 1330859
[TBL] [Abstract][Full Text] [Related]
19. Reduction of pulmonary metastases of B16 melanoma by human recombinant interleukin 2 and lymphokine-activated killer cells in immunosuppressed C57BL/6 mice receiving anticancer agent.
Saijo N; Ozaki A; Sakurai M; Ishihara J; Takahashi H; Sasaki Y; Hoshi A; Hamburger AW
Jpn J Cancer Res; 1986 May; 77(5):487-93. PubMed ID: 3089980
[TBL] [Abstract][Full Text] [Related]
20. Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells.
Yang JC; Mulé JJ; Rosenberg SA
J Immunol; 1986 Jul; 137(2):715-22. PubMed ID: 2873187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]